PTCT Q1 2019 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$5B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$54M-4.4% YoY

Gross Profit

$51M95.6% margin

Operating Income

-$69M-129.0% margin

Net Income

-$72M-134.6% margin

EPS (Diluted)

$-1.29

QoQ Revenue Growth

-37.9%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$45M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$771M

Stockholders' Equity

$513M

Cash & Equivalents

$407M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54M	$56M	-4.4%
Gross Profit	$51M	$53M	-3.4%
Operating Income	-$69M	-$17M	-312.9%
Net Income	-$72M	-$19M	-274.4%

Revenue Segments

Early Stage Collaborations

$252M100%

Licensing And Collaboration Agreement

$100,0000%